Hugh Young Rienhoff

Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA.

Emdeon Corp. offers services to connect physicians, hospitals, pharmacies, insurance providers, and consumers with health care transactions and information retrieval. Its transaction services encompass such tasks as HMO enrollment, referrals, data retrieval, and claims processing; its Medical Manager software helps physicians run their practices. The company was founded in December 1995 and is headquartered in Elmwood Park, NJ.

Part of AbbVie, Inc., DNA Sciences, Inc. is a private company that develops and produces in vitro diagnostic and research reagent products. The company is based in Fremont, CA. The company was founded by Hugh Young Rienhoff. DNA Sciences was acquired by Genaissance Pharmaceuticals, Inc., part of AbbVie, Inc. from October 07, 2005 on April 01, 2003 for $1.30 million.

Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix.

HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland.

WebMD, Inc. provides Internet-based services and information for physicians and health care information services for consumers

Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.